Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course
ranging from localized or spontaneously regressing to widely metastatic disease …

Interaction of the T cell receptor (TCR) with an MHC-antigenic peptide complex results in
changes at the molecular and cellular levels in T cells. The outside environmental cues are …

Background Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-
SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute …

Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

PURPOSE Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T
cells to engage and eliminate malignant B cells and is being developed for relapsed or …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

In the absence of cell surface cancer-specific antigens, immunotherapies such as chimeric
antigen receptor (CAR) T cells, monoclonal antibodies, or bispecific T cell engagers typically …

Background Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) have a relapse despite having a measurable residual disease (MRD)–negative …

Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …